UNSPSC 51330000: Antipsychotics

This classification denotes agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects.

UNSPSC 51330000 Antipsychotics is a Family code covering pharmaceuticals and related medical products that state and local governments procure for emergency medical services, health agency programs, and cooperative purchasing networks. Recent solicitation activity shows that state and local buyers are acquiring antipsychotic medications and related advanced life support drugs through competitive sealed bids, cooperative purchasing agreements, and exploratory requests for information. The issuing bodies include municipal fire rescue departments, state health agencies, and multistate cooperative purchasing alliances. The City of Tampa's Fire Rescue Department represents typical municipal procurement under this code—acquiring specific medication line items (Labetalol, Epinephrine, Adenosine, Diltiazem) with firm pricing, rapid delivery requirements, and expiration-date warranties. State health agencies are also active, as evidenced by the Texas Health and Human Services Commission's market intelligence gathering on direct-to-manufacturer prescription programs and the Minnesota Department of Administration's cooperative purchasing vehicle for generic pharmaceuticals and OTC products across multiple state and local facilities.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) reaching the broadest footprint through its multistate membership. Recent representative opportunities include the City of Tampa's IFB for Advanced Life Support Medications (Bid No. 26-P-00188, due April 8, 2026, estimated value $40,000, with a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount), the Texas HHS Commission's RFI on Direct-to-Manufacturer Prescriptions (HHS0017013, response deadline April 3, 2026, framing future formal procurement), and the Minnesota Department of Administration's RFP for Generic Multi Source Pharmaceuticals and OTC Products through MMCAP (S1070000015802, due March 26, 2026, with contract term beginning July 1, 2026 and pricing weighted at 75 percent of evaluation score). Vendors supplying under this code typically face requirements for FDA compliance, cGMP certification, Drug Supply Chain Security Act attestation, comprehensive insurance coverage, and Safety Data Sheets or accessibility documentation depending on the issuing body's standards.